These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37053347)

  • 1. [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
    Oliushina EM; Zavalishina LE; Alekseenok EY; Oskina NA; Andreeva YY; Kuznetsova OA; Filipenko ML; Frank GA
    Arkh Patol; 2023; 85(2):5-12. PubMed ID: 37053347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
    Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
    BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive markers of immunotherapy in cervical cancer].
    Oliushina EM; Zavalishina LE; Andreeva YY; Kuznetsova OA; Moskvina LV; Frank GA
    Arkh Patol; 2023; 85(5):5-12. PubMed ID: 37814844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
    Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
    Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
    Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
    Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
    Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
    Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
    Sungu N; Kıran MM
    Pol J Pathol; 2023; 74(3):161-170. PubMed ID: 37955535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
    Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
    Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
    Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
    Mertens LS; Claps F; Mayr R; Bostrom PJ; Shariat SF; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; Peters D; van der Heijden MS; Jewett MAS; Stöhr R; Zlotta AR; Eckstein M; Soorojebally Y; van der Schoot DKE; Wullich B; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; van der Kwast TH; Hartmann A; Lotan Y; Allory Y; Zuiverloon TCM; van Rhijn BWG
    Urol Oncol; 2022 Mar; 40(3):110.e1-110.e9. PubMed ID: 34906411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence.
    Monteiro CRA; Korkes F; Krutman-Zveibil D; Glina S
    Einstein (Sao Paulo); 2022; 20():eAO6450. PubMed ID: 35384983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
    Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
    J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
    Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
    Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
    Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
    Blinova E; Samishina E; Deryabina O; Blinov D; Roshchin D; Shich E; Tumutolova O; Fedoseykin I; Epishkina A; Barakat H; Kaprin A; Zhandarov K; Perepechin D; Merinov D; Brykin G; Arutiunian K; Serebrianyi S; Mirontsev A; Kozdoba A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
    Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
    Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?
    van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM
    Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.